Abstract
AbstractA series of novel N‐(3‐((6‐bromopyrido[2,3‐d]pyrimidin‐4‐yl)oxy)phenyl)pyrrolidine‐1‐carboxamide and 1‐(3‐((6‐bromopyrido[2,3‐d]pyrimidin‐4‐yl)oxy)phenyl)‐3‐propylurea derivatives were synthesized. Their antitumor activities against human breast carcinoma cells (MCF‐7) and human colon cancer cells (HCT‐116) in vitro were evaluated, using sorafenib as a positive control drug. Anticancer bioassays indicated that several compounds exhibited appreciable anticancer activity against MCF‐7 and HCT‐116 cells. Particularly, compounds 9g and 8b demonstrated the most significant inhibitory effect against HCT‐116 and MCF‐7 cells, with inhibition ratios of 25.56% and 26.46%, respectively. Additionally, the synthesized pyridine[2,3‐d]pyrimidine derivatives containing a urea group moieties exhibited antitumor activities against MCF‐7 and HCT‐116 cells in vitro.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
